2010s

This section contains reports and assessments published or updated during the years 2010 - 2019.

European Food Safety Authority (European Union).

July 2014

Following a request from the European Commission to address the risks and benefits as regards fish/seafood consumption related to relevant beneficial substances (e.g. nutrients such as n‐3 long‐chain polyunsaturated fatty acids) and the contaminant methylmercury, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver a Scientific Opinion on health benefits of seafood consumption in relation to health risks associated with exposure to methylmercury. In the present Opinion, the NDA Panel has reviewed the role of seafood in European diets and evaluated the beneficial effects of seafood consumption in relation to health outcomes and population subgroups that have been identified by the FAO/WHO Joint Expert Consultation on the Risks and Benefits of Fish Consumption and/or the EFSA Panel on Contaminants in the context of a risk assessment related to the presence of mercury and methylmercury in food as relevant for the assessment. These included the effects of seafood consumption during pregnancy on functional outcomes of children's neurodevelopment and the effects of seafood consumption on cardiovascular disease risk in adults. The Panel concluded that consumption of about 1‐2 servings of seafood per week and up to 3‐4 servings per week during pregnancy has been associated with better functional outcomes of neurodevelopment in children compared to no consumption of seafood. Such amounts have also been associated with a lower risk of coronary heart disease mortality in adults and are compatible with current intakes and recommendations in most of the European countries considered. These associations refer to seafood per se andinclude beneficial and adverse effects of nutrients and non‐nutrients (i.e. including contaminants such as methylmercury) contained in seafood. No additional benefits on neurodevelopmental outcomes and no benefit on coronary heart disease mortality risk might be expected at higher intakes.

Food and Agriculture Organization of the United Nations and World Health Organization (United Nations).

July 2014

Determines the feasibility of developing general guidance as a framework for annexes that would address specific parasite-commodity combinations. Defines how the various parasites were ranked, draws conclusions on these findings, and discusses risk management considerations.

Food Standards Agency (United Kingdom).

July 2014

Provides guidance on the steps for food businesses to take in order to control cross-contamination between raw foods that are a potential source of E. coli O157 and ready-to-eat foods. Applies across the United Kingdom.

Center for Food Safety and Applied Nutrition (Food and Drug Administration [United States Department of Health and Human Services]).

June 2014

Provides the Food and Drug Administration's (FDA) current thinking about the requirements in the final rule for eligible infant formulas. It answers questions about the quality factor requirements, record requirements, and voluntary submission of a citizen petition.

Food and Drug Administration (United States Department of Health and Human Services).

June 2014

Provides guidance to help manufacturers, suppliers, importers and other stakeholders with the application of nanotechnology in products. Describes whether Food and Drug Administration (FDA)-regulated products contain nanomaterials or otherwise involve the application of nanotechnology.

Centers for Disease Control and Prevention (United States Department of Health and Human Services).

May 2014

Summarizes the progress and the outcomes of the implementation of the 17 recommendations for future collaborations between the United States and the European Union in three key areas: appropriate therapeutic use of antimicrobial drugs in medical and veterinary communities, prevention of healthcare- and community-associated drug-resistant infections, and strategies for improving the pipeline of new antimicrobial drugs.

Food and Drug Administration (United States Department of Health and Human Services).

April 2014

Summarizes the eight initiatives and the recommendations from the relevant working groups for enhancing transparency and public accessibility of its compliance and enforcement data.

European Food Safety Authority and European Centre for Disease Prevention and Control (European Union).

April 2014

European Food Safety Authority (EFSA) and European Centre for Disease Prevention and Control (ECDC) update their rapid outbreak assessment as more than 1,300 hepatitis A cases being reported in eleven member States since January 2013. Of these, 240 were confirmed outbreak cases. Epidemiological, microbiological and environmental investigations indicate frozen berries as the vehicle of infection for this outbreak and suggest that it could be a single outbreak, linked to a common, continuous source in the EU/EEA. However other hypotheses cannot be excluded, such as cross contamination in a food production environment or an outbreak strain that is already widespread but has, to date, gone undetected.

European Food Safety Authority (European Union).

April 2014

From aspartame to zoonoses, EFSA’s scientists had another busy year in 2013. The Authority published more than 600 scientific outputs as it carried out its scheduled programme of risk assessments and met requests for urgent advice on issues such as the hepatitis A outbreak, the horsemeat crisis, and the risk of Rift Valley fever entering the EU.

World Health Organization (United Nations).

April 2014

Produced in collaboration with Member States and other partners, provides for the first time, as accurate a picture as is presently possible of the magnitude of Anti-microbial Resistance (AMR) and the current state of surveillance globally.

Pages